FrancophonIA/ELRC3.0 huggingface dataset:
English: Psoriasis study III (REACH) compared the efficacy and safety of adalimumab versus placebo in 72 patients with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis.
Croatian: U ispitivanju Psoriasis Study III (REACH) uspoređivale su se djelotvornost i sigurnost adalimumaba u odnosu na placebo u 72 bolesnika s umjerenom do teškom kroničnom plak psorijazom i psorijazom šaka i/ili stopala.
English: • If your child has an infection, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting Kromeya.
Croatian: • Ako Vaše dijete boluje od infekcije, uključujući dugotrajnu ili lokaliziranu infekciju (primjerice, ulceraciju na nozi), obratite se liječniku prije nego počnete primjenjivati lijek Kromeya.
English: Get Familiar with your Kromeya Pre-Filled Syringe Before Use
Croatian: Upoznajte Kromeya napunjenu brizgalicu Prije uporabe
English: Ulcerative colitis
Croatian: • ulceroznog kolitisa
English: PASI 75 and PGA of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).
Croatian: Stopa odgovora PASI 75 i PGA rezultata “bez bolesti” i “minimalno” je u tih bolesnika iznosila 74,7%, odnosno 59,0% nakon dodatnih 108 tjedana otvorene terapije (ukupno 160 tjedana).
English: RA studies III and V had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray results).
Croatian: Dodatni primarni ishod ispitivanja RA III i V bilo je usporavanje progresije bolesti (na temelju radioloških nalaza) nakon 52 tjedna liječenja.
English: 6.7 If there is blood or liquid on the injection site, gently press a clean cotton ball or gauze on the skin for 10 seconds.
Croatian: 6.7 U slučaju krvi ili tekućine na mjestu injiciranja, nježno na kožu na 10 sekundi pritisnite kuglicu od vate ili gazu.
English: Kromeya is injected under the skin (subcutaneous use).
Croatian: Kromeya se ubrizgava pod kožu (supkutana primjena).
English: 6 months 6.7% 12 months NA
Croatian: 6 mjeseci 12 mjeseci
English: In adult Crohn's disease studies, higher incidences of malignant and serious infection-related adverse events were seen with the combination of adalimumab and azathioprine/6-mercaptopurine compared with adalimumab alone.
Croatian: U ispitivanjima kod Crohnove bolesti u odraslih, kod kombinacije adalimumaba i azatioprina/6-merkaptopurina primijećene su veće incidencije nuspojava povezanih sa zloćudnim bolestima i ozbiljnim infekcijama nego kod primjene samo adalimumaba.
English: 4.3 Pull the needle packaging off.
Croatian: 4.3 Povucite pakiranje igle i skinite ga s igle.
English: The Kromeya pre-filled syringe is supplied in a glass syringe with needleguard and finger flanges.
Croatian: Kromeya napunjena štrcaljka dolazi kao staklena štrcaljka sa štitnikom za iglu i hvatištem za prste.
English: Tell your doctor if your child is taking azathioprine or mercaptopurine with Kromeya.
Croatian: Obavijestite liječnika ako Vaše dijete istodobno uz lijek Kromeya uzima azatioprin ili merkaptopurin.
English: • The name on the vial is not Kromeya.
Croatian: • ime na bočici nije Kromeya.
English: Step 7 Throw away your Syringe
Croatian: 7. korak Bacite štrcaljku
English: Patients received either placebo or 20 mg adalimumab (if < 30 kg) or 40 mg adalimumab (if ≥ 30 kg) every other week in combination with their baseline dose of methotrexate.
Croatian: Bolesnici su primali ili placebo ili 20 mg adalimumaba (ako su bili tjelesne težine < 30 kg) odnosno 40 mg adalimumaba (ako su bili tjelesne težine ≥ 30 kg) svaki drugi tjedan u kombinaciji s metotreksatom u dozi koju su primali na početku ispitivanja.
English: Usually, Kromeya is used with methotrexate.
Croatian: Kromeya se obično primjenjuje u kombinaciji s metotreksatom.
English: Clinical response is decrease from baseline in Mayo score ≥ 3 points and ≥ 30% plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS of 0 or 1; p < 0.05 for adalimumab vs. placebo pairwise comparison of proportions **p < 0.001 for adalimumab vs. placebo pairwise comparison of proportions a
Croatian: Klinička remisija je Mayo rezultat ≤ 2 bez podrezultata > 1; Klinički odgovor je postignut ako je ostvareno smanjenje Mayo rezultata u odnosu na početne vrijednosti od ≥ 3 boda i ≥ 30%, uz smanjenje podrezultata rektalnog krvarenja [engl. rectal bleeding subscore, RBS] od ≥1 ili apsolutni RBS od 0 ili 1; * p<0,05 za adalimumab naspram placeba, sparena usporedba udjela ** p<0,001 za adalimumab naspram placeba, sparena usporedba udjela a onih koji su na početku uzimali kortikosteroide
English: Table 8 Ped ACR 30 responses in the JIA study
Croatian: Tablica 8 Pedijatrijski odgovori ACR 30 u ispitivanju kod JIA
English: Step 3 Check the Syringe
Croatian: 3. korak Provjerite štrcaljku
English: For patients who dose escalated from eow to weekly regimen, the mean (±SD) serum concentrations of adalimumab at week 52 were 15.3±11.4 μg/mL (40/20 mg, weekly) and 6.7±3.5 μg/mL (20/10 mg, weekly).
Croatian: U bolesnika čija je učestalost doziranja povišena sa svaka dva tjedna na svaki tjedan, srednje vrijednosti (±SD) koncentracija adalimumaba u serumu u 52. tjednu bile su 15,3 ± 11,4 μg/ml (40/20 mg, tjedno) i 6,7 ± 3,5 μg/ml (20/10 mg, tjedno).
English: Warning: Call your healthcare professional if you did not inject the full dose.
Croatian: Upozorenje: Ako niste injicirali cijelu dozu, nazovite svog liječnika.
English: If you accidentally inject a smaller amount of Kromeya liquid, or if you inject Kromeya less frequently than told to by your child's doctor or pharmacist, you should call your child's doctor or pharmacist and tell him/her that your child has taken less.
Croatian: Ako slučajno injektirate manju količinu tekućine lijeka Kromeya ili primijenite lijek Kromeya rjeđe nego je to preporučio liječnik ili ljekarnik, nazovite liječnika ili ljekarnika i objasnite im da je Vaše dijete primilo manju količinu.
English: • a cotton ball or gauze, and
Croatian: • jastučić od vate ili gaza i
English: The distribution of patients by age and minimum, median and maximum dose received during the OL LI phase is presented in Table 7.
Croatian: Raspored bolesnika prema dobi te minimalnoj i maksimalnoj dozi i medijanu doze tijekom ove faze prikazan je u Tablici 7.
English: The mean (±SD) serum adalimumab trough concentrations achieved at week 4 were 15.7±6.6 µg/mL for patients ≥ 40 kg (160/80 mg) and 10.6±6.1 µg/mL for patients < 40 kg (80/40 mg).
Croatian: Srednje vrijednosti (±SD) najnižih koncentracija adalimumaba u serumu u 4. tjednu bile su 15,7 ± 6,6 g/ml u bolesnika tjelesne težine ≥ 40 kg (160/80 mg) i 10,6 ± 6,1 g/ml u bolesnika tjelesne težine < 40 kg (80/40 mg).
English: Warning: Do not touch the needle.
Croatian: Upozorenje: Nemojte dirati iglu.
English: Patients should be tested for HBV infection before initiating treatment with Kromeya.
Croatian: Bolesnike je potrebno prije početka terapije lijekom Kromeya testirati na HBV infekciju.
English: Kromeya is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate.
Croatian: Kromeya je indicirana za liječenje neinfektivnog intermedijarnog, posteriornog i panuveitisa u odraslih bolesnika u kojih nije postignut zadovoljavajući odgovor na kortikosteroide, kojima je potrebna poštedna primjena kortikosteroida ili u kojih liječenje kortikosteroidima nije prikladno.
English: • As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check your child for signs and symptoms of tuberculosis before starting Kromeya.
Croatian: • Budući da su u bolesnika liječenih adalimumabom prijavljeni slučajevi tuberkuloze, prije nego počne s liječenjem lijekom Kromeya, liječnik će provjeriti kod Vašeg djeteta ima li znakove i simptome tuberkuloze.
English: It is recommended that the conduct and results of these tests are recorded in the patient reminder card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Croatian: Pritom liječnici koji propisuju lijek trebaju imati na umu da tuberkulinski kožni test može dati lažno negativne rezultate, pogotovo u teško bolesnih ili imunokompromitiranih bolesnika.
English: The safety and efficacy of adalimumab were assessed in a multicenter, randomised, double-blind study in 46 paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis.
Croatian: Sigurnost i djelotvornost primjene adalimumaba ocijenjena je u multicentričnom, randomiziranom, dvostruko slijepom ispitivanju koje je uključivalo 46 pedijatrijskih bolesnika (u dobi od 6 do 17 godina) s umjerenim artritisom povezanim s entezitisom.
English: On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship was established between plasma concentrations and PedACR 50 response.
Croatian: Na temelju podataka iz kliničkih ispitivanja u bolesnika s juvenilnim idiopatskim artritisom (poliartikularnim juvenilnim idiopatskim artritisom i artritisom povezanim s entezitisom), utvrđena je veza između plazmatskih koncentracija i odgovora PedACR 50.
English: Adalimumab, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II.
Croatian: Djelovanje adalimumaba u dozi od 40 mg svaka dva tjedna ispitivano je u bolesnika s umjereno teškim do teškim aktivnim psorijatičnim artritisom u dva placebom kontrolirana ispitivanja, ispitivanja PsA I i II.
English: In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 12).
Croatian: U ispitivanju RA V, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema Sharpu (Tablica 12).
English: 20 mg every other week
Croatian: 20 mg svaki drugi tjedan
English: Kromeya dose for patients with polyarticular juvenile idiopathic arthrtis
Croatian: Doza lijeka Kromeya za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom
English: If these medicines do not work well enough, your child will be given Kromeya to treat his/her polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis.
Croatian: Ako ti drugi lijekovi ne djeluju dovoljno dobro, Vašem djetetu će biti propisan lijek Kromeya u svrhu liječenja njihovog poliartikularnog juvenilnog idiopatskog artritisa ili artritisa povezanog s entezitisom.
English: 2.2 Check the label on the vial for Kromeya and expiration date.
Croatian: 2.2 Provjerite ime Kromeya i rok valjanosti na naljepnici bočice.
English: If these medicines do not work well enough, patients will be given Kromeya to treat their polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis.
Croatian: Ako ti drugi lijekovi ne djeluju dovoljno dobro, bolesnicima će biti propisan lijek Kromeya u svrhu liječenja njihovog poliartikularnog juvenilnog idiopatskog artritisa ili artritisa povezanog s entezitisom.
English: In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 10).
Croatian: U ispitivanju RA V, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema Sharpu (Tablica 10).
English: You should record the date when the pen is first removed from refrigerator, and the date after which it should be discarded.
Croatian: Zabilježite datum kada ste bočicu prvi put izvadili iz hladnjaka i datum nakon kojega je morate baciti.
English: In RA study III, where adalimumab treated patients had a mean duration of rheumatoid arthritis of approximately 11 years, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.
Croatian: U ispitivanju RA III, u kojem je srednje trajanje reumatoidnog artritisa u bolesnika liječenih adalimumabom bilo 11 godina, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema modificiranoj Sharpovoj ljestvici (engl.
English: Kromeya should be used with caution in patients with mild heart failure (NYHA class I/II).
Croatian: Zato se bolesnicima s blagim zatajenjem srca (NYHA razred I/II) Kromeya mora davati oprezno.
English: A total of 76.5% (218/285) of patients who entered the retreatment period had a response of PGA “clear” or “minimal” after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively).
Croatian: Ukupno je 76,5% (218/285) bolesnika kojima je liječenje ponovno uvedeno imalo PGA odgovor “bez bolesti” ili “minimalno” nakon 16 tjedana liječenja, bez obzira jesu li doživjeli relaps u razdoblju kada je liječenje bilo ukinuto (69,1%[123/178] za bolesnike s relapsom odnosno 88,8% [95/107] za bolesnike bez relapsa).
English: Warning: Do not rub the injection site.
Croatian: Upozorenje: Nemojte trljati mjesto injiciranja.
English: The combination of Kromeya and abatacept is not recommended (see section 4.4 “Concurrent administration of biologic DMARDs or TNF-antagonists”).
Croatian: Kombinirana terapija lijekom Kromeya i abataceptom se ne preporučuje (vidjeti dio 4.4 “ Istodobna primjena bioloških antireumatika koji modificiraju tijek bolesti ili antagonista TNF-a“).
English: These results suggest that some patients who have not responded by week 4 benefit from continued maintenance therapy through week 12.
Croatian: To pokazuje da neki bolesnici koji u 4. tjednu nisu imali klinički odgovor mogu imati koristi ako se terapija nastavi do 12. tjedna.
English: Your symptoms may return upon stopping treatment.
Croatian: Simptomi se mogu vratiti nakon prestanka primjene.
English: Kromeya is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.
Croatian: Kromeya je indicirana za liječenje aktivnog i progresivnog psorijatičnog artritisa u odraslih bolesnika u kojih prethodnim liječenjem antireumaticima koji modificiraju tijek bolesti nije postignut zadovoljavajući odgovor.
English: • As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check you for signs and symptoms of tuberculosis before starting Kromeya.
Croatian: • Budući da su u bolesnika liječenih adalimumabom prijavljeni slučajevi tuberkuloze, prije nego počnete s liječenjem lijekom Kromeya, liječnik će provjeriti imate li znakove i simptome tuberkuloze.
English: 7.1 Now that you have completed your injection, update your record with:
Croatian: Nakon što ste uspješno injicirali lijek, u svoje bilješke upišite:
English: The safety and efficacy of adalimumab were also studied in adult patients with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-blind study (Psoriasis study III).
Croatian: Sigurnost i djelotvornost adalimumaba također se ispitivala u odraslih bolesnika s umjerenom do teškom kroničnom plak psorijazom i istodobnom psorijazom šaka i/ili stopala koji su bili kandidati za sistemsku terapiju u randomiziranom, dvostruko slijepom ispitivanju (Psoriasis Study III).
English: In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 showed greater improvement (p < 0.001) for adalimumab/methotrexate combination therapy versus methotrexate monotherapy and adalimumab monotherapy at week 52, which was maintained through week 104.
Croatian: U ispitivanju RA V, poboljšanje indeksa onesposobljenosti HAQ i fizičke komponente SF 36 nakon 52 tjedna bilo je veće u bolesnika liječenih kombinacijom adalimumaba i metotreksata (p < 0,001) u usporedbi s bolesnicima koji su dobivali monoterapiju metotreksatom, odnosno adalimumabom, i to se poboljšanje održalo tijekom 104 tjedna liječenja.
English: Kromeya contains sodium
Croatian: Kromeya sadrži natrij
English: Erythema multiforme Stevens-Johnson syndrome angioedema cutaneous vasculitis lichenoid skin reaction
Croatian: Stevens-Johnsonov sindrom angioedem kutani vaskulitis1) lihenoidne kožne reakcije nepoznato pogoršanje simptoma dermatomiozitisa1)
English: Discontinuation of immunomodulators
Croatian: Prekinuti imunomodulatori
English: Kromeya is also used to treat severe plaque psoriasis in children and adolescents adolescents aged 4 to 17 years for whom medicines applied to the skin and treatment with UV light have either not worked very well or are not suitable.
Croatian: Kromeya se koristi i za liječenje teške plak psorijaze u djece i adolescenata u dobi od 4 do 17 godina u kojih lijekovi koji se nanose na kožu i terapije s UV svjetlom nisu djelovale jako dobro ili nisu prikladne.
English: The efficacy of adalimumab was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA ≥ 4 or > 20% BSA involvement or > 10% BSA involvement with very thick lesions or PASI ≥ 20 or ≥ 10 with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.
Croatian: Djelotvornost adalimumaba ocjenjivala se u randomiziranom, dvostruko slijepom, kontroliranom ispitivanju provedenom u 114 pedijatrijskih bolesnika u dobi od 4 ili više godina s teškom kroničnom plak psorijazom (koja se definirala kao PGA rezultat od ≥ 4 ili zahvaćenost površine tijela od > 20% ili zahvaćenost površine tijela od > 10% s vrlo debelim lezijama ili PASI rezultat od ≥ 20 ili ≥ 10 uz klinički značajnu zahvaćenost lica, genitalija ili šaka/stopala) u kojih bolest nije bila dovoljno dobro kontrolirana topikalnom terapijom i helioterapijom ili fototerapijom.
English: eye infections,
Croatian: • infekcije oka,
English: All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of nonmelanoma skin cancer prior to and during treatment with Kromeya.
Croatian: Sve bolesnike, a posebno one koji u anamnezi imaju dugotrajno korištenje imunosupresivne terapije ili bolesnike s psorijazom i PUVA liječenjem u anamnezi, potrebno je prije i za vrijeme liječenja lijekom Kromeya pregledavati u svrhu otkrivanja nemelanomskog karcinoma kože.
English: Upon completion of the first 104 weeks, 497 patients enrolled in an open-label extension phase in which 40 mg of adalimumab was administered every other week up to 10 years.
Croatian: Po završetku prva 104 tjedna, 497 bolesnika uključeno je u otvoreni produžetak ispitivanja u kojem se adalimumab u dozi od 40 mg primjenjivao svaka dva tjedna tijekom razdoblja do 10 godina.
English: You are advised to avoid becoming pregnant and must use adequate contraception while using Kromeya and for at least 5 months after the last Kromeya injection.
Croatian: Preporučuje se da za vrijeme korištenja lijeka Kromeya ne ostanete trudni, a odgovarajuću kontracepciju morate koristiti još barem 5 mjeseci nakon posljednje injekcije lijeka Kromeya.
English: • The Kromeya pre-filled pen comes as a ready to use single-use pre-filled pen to give a full dose of adalimumab.
Croatian: • Kromeya je napunjena brizgalica spremna za uporabu i davanje pune doze adalimumaba te je namijenjena samo za jednokratnu uporabu.
English: b p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test c p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann-Whitney U test
Croatian: JSN rezultat p-vrijednost dobivena sparenom usporedbom monoterapije metotreksatom i kombinirane terapije adalimumabom i metotreksatom uz primjenu Mann-Whitney U testa bp-vrijednost dobivena sparenom usporedbom monoterapije adalimumabom i kombinirane terapije adalimumabom i metotreksatom uz primjenu Mann-Whitney U testa p-vrijednost dobivena sparenom usporedbom monoterapije adalimumabom i monoterapije metotreksatom uz primjenu Mann-Whitney U testa
English: Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 27).
Croatian: Rezultati iz obaju ispitivanja pokazali su statistički značajno smanjenje rizika od neuspjeha liječenja u bolesnika liječenih adalimumabom u odnosu na one koji su primali placebo (vidjeti Tablicu 27).
English: If you accidentally inject a larger amount of Kromeya liquid, or if you inject Kromeya more frequently than told to by your doctor, call your doctor and tell him/her that your child has taken more.
Croatian: Ako slučajno injektirate veću količinu tekućine lijeka Kromeya ili primijenite lijek Kromeya češće nego je to preporučio liječnik, nazovite liječnika ili ljekarnika i objasnite im da je Vaše dijete primilo veću količinu.
English: All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Kromeya.
Croatian: Bolesnike treba upozoriti da se odmah obrate liječniku ako se za vrijeme liječenja lijekom Kromeya pojave znakovi i simptomi koji upućuju na krvne diskrazije (npr. stalna vrućica, stvaranje (nastanak) modrica, krvarenje, bljedilo).
English: The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of pivotal studies was 5.9% for patients taking adalimumab and 5.4% for control treated patients.
Croatian: U dvostruko slijepim, kontroliranim dijelovima pivotalnih ispitivanja, liječenje je zbog štetnih događaja prekinuto u 5,9% bolesnika koji su dobivali adalimumab, odnosno 5,4% bolesnika iz kontrolne skupine.
English: Results from the Short Form Health Survey (SF 36) for all doses/schedules of adalimumab in all four studies support these findings, with statistically significant physical component summary (PCS) scores, as well as statistically significant pain and vitality domain scores for the 40 mg every other week dose.
Croatian: Short Form Health Survey, SF 36) podupiru te nalaze za sve doze/režime davanja adalimumaba u sva četiri ispitivanja, sa statistički značajnim rezultatom za cjelokupnu fizičku komponentu (engl.
English: Doses of 20 or 40 mg of adalimumab were given by subcutaneous injection every other week with placebo on alternative weeks or every week for 26 weeks; placebo was given every week for the same duration.
Croatian: Adalimumab u dozi od 20 ili 40 mg primjenjivao se ili svaki drugi tjedan naizmjenično s placebom (jedan tjedan adalimumab, drugi tjedan placebo), ili svaki tjedan tijekom 26 tjedana; placebo se primjenjivao svaki tjedan tijekom istog razdoblja.
English: The incidence of serious infections was 0.04 per patient year in adalimumab treated patients and 0.03 per patient year in placebo and active control − treated patients.
Croatian: Incidencija ozbiljnih infekcija bila je 0,04 po bolesnik-godini u bolesnika liječenih adalimumabom, odnosno 0,03 po bolesnik-godini u onih koji su primali placebo ili aktivni kontrolni lijek.
English: Study UV I
Croatian: Ispitivanje UV I
English: The combination of Kromeya and anakinra is not recommended (see section 4.4 “Concurrent administration of biologic DMARDs or TNF-antagonists”).
Croatian: Kombinirana terapija lijekom Kromeya i anakinrom se ne preporučuje (vidjeti dio 4.4 “Istodobna primjena bioloških antireumatika koji modificiraju tijek bolesti ili antagonista TNF-a“).